October 7, 2022
3:30 PM AEST / AEDT Australia | 12:30 PM Singapore / 1:30 PM Korea, Japan | 10:00 AM India
Targeted sequence analysis from preclinical research through manufacturing
Join us for a webinar to learn about the use of Sanger sequencing and fragment analysis across a broad range of applications—from confirmation of sequences during molecular biology applications and gene editing to sample and cell line authentication and manufacturing quality control (QC)—including the recent application in mRNA vaccine identity testing.
Key topics:
- Effective application of targeted sequence analysis to propel the biopharmaceutic development continuum from pre-clinical research and biomarker discovery through manufacturing
- Paradigm shift in the field of vaccinology – mRNA
Speakers:
Dr. Edgar Schreiber
Sr. Staff Product Applications Specialist
Thermo Fisher Scientific, USA
Effective application of targeted sequence analysis to propel the biopharmaceutic development continuum from pre-clinical research and biomarker discovery through manufacturing
Dr Schreiber received his PhD in 1990 for research on transcription enhancers and did postdoctoral studies in Zurich and at Stanford University. In 1997, he joined what was then Applied Biosystems™ as a Research and Development Scientist. He has led and contributed to multiple product developments and launches, including kits for food pathogen detection and typing, genetic diseases. In his current role as a product application specialist at Thermo Fisher, he is focusing on the development and support of sequencing and fragment analysis applications for the capillary electrophoresis-based Applied Biosystems™ Genetic Analyzer platform.
Dr. Ajay Singh
Head of mRNA Department
Gennova Biopharmaceuticals, India
Paradigm shift in the field of vaccinology – mRNA
Dr Singh accomplished his doctorate in biochemistry from South Campus Delhi University, New Delhi, India. Dr Singh is part of Gennova since 2013 and has widened his horizon by working on various domains. His heart of research at Gennova is mRNA vaccines, therapeutics, antibody engineering, production and localization studies. From the first moments of COVID-19 pandemic, he is working diligently for the development of first fully indigenous mRNA vaccine in India. His group of astute scientists have also made advances addressing the SARS-CoV-2 variants through next era of vaccinology and mRNA vaccines.